1B

Enlivex Therapeutics LtdFRA Enlivex Stock Report

Last reporting period 30 Sep, 2023

Updated 02 Dec, 2024

Last price

Market cap $B

0.032

Micro

Exchange

XFRA - Deutsche Boerse AG

1BT.F Stock Analysis

1B

Uncovered

Enlivex Therapeutics Ltd is uncovered by Eyestock quantitative analysis.

Market cap $B

0.032

Dividend yield

Shares outstanding

18.403 B

Enlivex Therapeutics Ltd. is a clinical stage macrophage reprogramming immunotherapy company, which develops Allocetra,a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

View Section: Eyestock Rating